Targeting Podoplanin to Combat Cancer
Technology
Sentrimed® is launching its first product, MASL®, to treat and prevent cancer and arthritis. Our technology is protected by issued patents and proprietary technology tailored to combat cancer and inflammatory diseases by targeting a unique receptor, called podoplanin (PDPN), which is expressed by cancer and inflammatory cells. We have received IRB approval from major universities and hospitals & IND approval from the USFDA for a Phase 1 clinical trial, with a potential for fast track designation to combat oral cancer and precancerous lesions. We are uniquely positioned to change the paradigm currently used to treat cancer and arthritis in a patient specific manner based on individualized therapy. We offer dynamic opportunities for accelerated approval, orphan drug designation, as well as combination therapies for multiple indications. We are seeking an investment partner in return for a significant stake in the venture at this stage of development.
Competitive Advantages
- The proposed technology can be isolated relatively cheaply from many naturally occurring species in large abundance
- The proposed therapy could potentially be applied to a broad range of metastatic solid tumor cancers
- the proposed therapy is not toxic - which is a rare property for cancer treatments
- The proposed therapy is resistant to gastrointestinal proteolysis and can be taken via oral administration, which open avenues for nutraceutical and companion animal markets in addition to pharmaceutical applications.
Market
The oncology drug market exceeds $150 billion and is growing at an annual rate of 7.5 – 10.5 percent. We are poised to enter this market.
Patent Information:
| Title |
App Type |
Country |
Serial No. |
Patent No. |
File Date |
Issued Date |
Expire Date |
Patent Status |
| Targeting Podoplanin to Block Tumor Cell Migration |
US Provisional |
United States |
61/069,198 |
|
3/12/2008 |
|
3/12/2009 |
Expired |
| Cancer Biomarker Genes and Gene Products and Methods for Using the Same |
US Non-Provisional |
United States |
12/401,849 |
8,114,593 |
3/11/2009 |
2/14/2012 |
7/2/2029 |
Issued |
| Targeting Of Podoplanin With Lectin For Use In The Prevention and Treatment Of Cancer |
US Continuation-in-Part |
United States |
13/218,717 |
9,169,327 |
8/26/2011 |
10/27/2015 |
|
Issued |
| Targeting of Podoplanin with Lectin for Use in the Prevention and Treatment of Cancer |
US Continuation |
United States |
14/921,641 |
9,809,631 |
10/23/2015 |
8/29/2017 |
|
Issued |
|
|
|
Inventors:
Keywords:
|
